Analysis of the codon 72 polymorphism of TP53 and human papillomavirus infection in Iranian patients with prostate cancer

Journal of Medical Virology

Volumn 84, Issue 9, 2012, Pages 1423-1427

  Salehi, Zivar ^a   Hadavi, Mahvash ^a  

^a UNIVERSITY OF GUILAN   (Iran)

Author keywords

Arg72 Pro; Genetic polymorphism; HPV; P53; Prostate cancer

Indexed keywords

ARGININE; GENOMIC DNA; PROLINE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CODON; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; GLEASON SCORE; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; CODON; DNA, VIRAL; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; IRAN; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

HUMAN PAPILLOMAVIRUS;

EID: 84864115883     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23268     Document Type: Article

References (26)

1. Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A, Beckman L. 1994. Is p53 polymorphism maintained by natural selection? Hum Hered 44: 266-270.
2. Chang CY, Walther PJ, McDonnell DP. 2001. Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 61: 8712-8717.
3. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, Anderson M, Kocjan G, Steele ST, Guillebaud J. 1995. Human papillomavirus testing in primary cervical screening. Lancet 345: 1533-1536.
4. Dennis LK, Hayes RB. 2001. Alcohol and prostate cancer. Epidemiol Rev 23: 110-114.
5. Ferrís-Tortajada J, Berbel-Tornero O, García-Castell J, Ortega-García JA, López-Andreu JA. 2011. Dietetic factors associated with prostate cancer. Protective Effects of Mediterranean Diet. Actas Urol Esp in press.
6. Giovannucci E, Tosteson TD, Speizer FE, Ascherio A, Vessey MP, Colditz GA. 1993. A retrospective cohort study of vasectomy and prostate cancer in US men. JAMA 269: 878-882.
7. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J, Chang C. 2000. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China. Cancer Res 60: 5111-5116.
8. Korodi Z, Dillner J, Jellum E, Lumme S, Hallmans G, Thoresen S, Hakulinen T, Stattin P, Luostarinen T, Lehtinen M, Hakama M. 2005. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: A Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 14: 2952-2955.
9. Koushik A, Platt RW, Franco EL. 2004. p53 codon 72 polymorphism and cervical neoplasia. Cancer Epidemiol Biomarkers Prev 13: 11-22.
10. Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, Eiguchi K. 2005. Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol 5: 1-7.
11. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. 1987. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7: 961-963.
12. Nelson WG, De Marzo AM, Isaacs WB. 2003. Prostate cancer. N Engl J Med 349: 366-381.
13. Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. 2010. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer 126: 1187-1195.
14. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein AJ, Malkowicz SB. 2000. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 67: 1014-1019.
15. Robles AI, Linke SP, Harris CC. 2002. The p53 network in lung carcinogenesis. Oncogene 21: 6898-6907.
16. Saad F, Gu K, Jean-Baptiste J, Gauthier J, MesMasson AM. 1999. Absence of human papillomavirus sequences in early stage prostate cancer. Can J Urol 6: 834-838.
17. Safarinejad MR. 2006. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol 17: 1166-1171.
18. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK, Manos MM. 1993. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85: 958-964.
19. Serth J, Panitz F, Paeslack U, Kuczyk MA, Jonas U. 1999. Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res 59: 823-825.
20. Singal R, Ferdinand L, Das PM, Reis IM, Schlesselman JJ. 2004. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Int J Oncol 25: 1465-1471.
21. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. 1998. Role of a p53 polymorphism in the development of human papilloma virus-associated cancer. Nature 393: 229-234.
22. Strickler HD, Burk R, Shah K, Viscidi R, Jackson A, Pizza G, Bertoni F, Schiller JT, Manns A, Metcalf R, Qu W, Goedert JJ. 1998. A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 82: 1118-1125.
23. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408: 307-310.
24. Weijerman PC, van Drunen E, König JJ, Teubel W, Romijn JC, Schröder FH, Hagemeijer A. 1997. Specific cytogenetic aberrations in two novel human prostatic cell lines immortalized by human papillomavirus type 18 DNA. Cancer Genet Cytogenet 99: 108-115.
25. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA. 2002. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32: 321-325.
26. Zhang J, Zhuo WL, Zheng Y, Zhang YS. 2010. Polymorphisms of TP53 codon 72 with prostate carcinoma risk: A meta-analysis. Med Oncol 27: 540-546.